Angiotech begins enrollment in hemodialysis safety trial

By Elaine Rigoli

Tampa, Fla., Aug. 17 - Angiotech Pharmaceuticals, Inc. will begin enrollment in a clinical trial in the United Kingdom to assess the effectiveness and safety of the Vascular Wrap paclitaxel-eluting mesh and Lifespan graft technology platform in hemodialysis patients.

The trial will determine whether hemodialysis patients who receive the Vascular Wrap paclitaxel-eluting mesh/Lifespan graft combination product experience fewer graft failures than those patients that receive the Lifespan graft alone.

As a combination product, the graft serves as an access port for hemodialysis, and the intent of the drug-eluting mesh is to prevent the scar formation that often leads to graft failure, the company said in a news release.

Angiotech said it expects to enroll the first patient in the next eight weeks. The company also intends to conduct a similar trial in the United States. Both trials are expected to be about 24 months in duration, with enrollment taking about one year.

The goal of the studies is to provide Angiotech with sufficient data to submit to regulatory authorities for the approval to market the products in the United States and Europe.

Angiotech is a pharmaceutical and medical device company based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.